The FDA announced that bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Eli Lilly and its authorized distributors have paused commercial distribution of bebtelovimab until further notice by the Agency, the FDA stated.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY:
- Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases
- Eli Lilly’s (NYSE:LLY) COVID-19 Therapy Loses FDA Authorization
- Biogen Alzheimer’s data increases approval confidence, says JPMorgan
- Lilly and Akouos Announce Expiration of Akouos Tender Offer
- Prothena data from AD/PD abstract ‘promising,’ says Jefferies
